Evaluation of Organized Human Papilloma Virus (HPV) Screening of 23-29-year-old Women
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Human Papilloma Virus
- Sponsor
- Karolinska Institutet
- Enrollment
- 180000
- Locations
- 2
- Primary Endpoint
- Incidence of cervical cancer
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
The aim of the trial is to determine whether organized screening with primary HPV analysis provide higher cancer protection in the age group 23-29 years compared to primary cytology.
Detailed Description
The aim is to investigate whether primary HPV analysis in the organized cell sampling program for women in the age group 23-29 provides higher cancer protection compared to the current method where cell samples are primarily analyzed with cytology. In this study, all women in the age group 23-29 in the Stockholm and Skåne Region of Sweden will participate. Age is defined by year of birth. For 2020, women born 1991-1997 are included. Sampling and collection of samples is the same as for cytology.
Investigators
Joakim Dillner
Professor of Infectious Disease Epidemiology; Director of R&D
Karolinska Institutet
Eligibility Criteria
Inclusion Criteria
- •Women ages 23-29 invited to screening.
Exclusion Criteria
- •Women who do not show up for screening or do not consent.
Outcomes
Primary Outcomes
Incidence of cervical cancer
Time Frame: Measured once during 1 year, year 10.
Cervical cancer incidence in the intervention group compared to a historical control group.
Secondary Outcomes
- Cost-effectiveness of the new screening method(Measured once during 1 year, year 10.)